Drugs / AZD2816
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT04973449 | Jun 2021 → Feb 2022 | COVID-19 | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD2816 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04973449 ↗ |
| Modality | Vaccine | “AZD2816 is a variant-adapted COVID-19 vaccine” PMID 38878794 ↗ Jun 2024 |